Dr. Sunil Verma, medical oncologist at Sunnybrook Odette Cancer Centre explains how a new experimental drug combining trastuzumab (existing breast cancer drug) and emtansine (cancer-cell-destroying agent) appears to be effective in prolonging the life and reducing tumor growth in women in the late stages of HER2-positive breast cancer. By attacking cancer cells, yet preventing the release of chemotherapy until the drug reaches its target, "the treatment attacks cancer with greater power and effectiveness, yet less toxicity, so patients experience fewer side effects, such as nausea and vomiting, hair loss and infections."
To read more about this study, click here
Study mentioned: Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Oct 1. [Epub ahead of print]. PMID: 23020162
No comments:
Post a Comment